Voyager Therapeutics (NASDAQ:VYGR) Upgraded at StockNews.com

StockNews.com upgraded shares of Voyager Therapeutics (NASDAQ:VYGR) from a hold rating to a buy rating in a research note released on Saturday morning.

Several other analysts have also recently issued reports on the stock. Wedbush cut their price target on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th. HC Wainwright reiterated a “buy” rating and set a $30.00 target price on shares of Voyager Therapeutics in a research note on Thursday, October 24th. Leerink Partners started coverage on shares of Voyager Therapeutics in a research note on Wednesday, October 16th. They set an “outperform” rating and a $15.00 target price for the company. Finally, Leerink Partnrs upgraded shares of Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 16th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Voyager Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $17.43.

Voyager Therapeutics Stock Performance

Voyager Therapeutics stock opened at $6.65 on Friday. Voyager Therapeutics has a 1 year low of $5.71 and a 1 year high of $11.72. The firm has a 50 day moving average price of $6.57 and a 200 day moving average price of $7.56. The company has a market cap of $362.62 million, a price-to-earnings ratio of 25.00 and a beta of 0.89.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.20. Voyager Therapeutics had a net margin of 6.28% and a return on equity of 3.31%. The firm had revenue of $29.58 million for the quarter, compared to analysts’ expectations of $11.52 million. During the same period in the previous year, the company posted ($0.51) earnings per share. Sell-side analysts predict that Voyager Therapeutics will post -1.27 EPS for the current year.

Insider Activity

In other Voyager Therapeutics news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the business’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total value of $34,914.18. Following the sale, the insider now owns 86,001 shares in the company, valued at approximately $500,525.82. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 4.53% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Voyager Therapeutics

Several large investors have recently bought and sold shares of the company. Ameritas Investment Partners Inc. raised its position in shares of Voyager Therapeutics by 49.6% during the first quarter. Ameritas Investment Partners Inc. now owns 3,923 shares of the company’s stock worth $37,000 after acquiring an additional 1,300 shares during the last quarter. Plato Investment Management Ltd purchased a new position in Voyager Therapeutics in the first quarter worth $38,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Voyager Therapeutics by 64.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock valued at $61,000 after buying an additional 4,098 shares during the period. SG Americas Securities LLC bought a new stake in shares of Voyager Therapeutics in the second quarter valued at $85,000. Finally, ProShare Advisors LLC bought a new stake in shares of Voyager Therapeutics in the first quarter valued at $101,000. 48.03% of the stock is currently owned by institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.